华盛顿大学圣路易斯分校的研究发现，停止使用GLP-1类药物（包括Ozempic、Wegovy、Mounjaro和Zepbound）可能导致心血管保护作用迅速消退1。该研究追踪了超过333,000名患2型糖尿病的美国退伍军人三年，发现停药两年后患者的心脏病发作、中风和死亡风险比继续用药者高22%1。研究已发表于《BMJ医学》期刊1。
研究数据显示，26%的GLP-1使用者完全停药，另有约23%经历至少六个月的治疗间断1。即使仅中断六个月的治疗也足以减弱心血管保护作用，增加4-8%的风险1。持续用药三年的患者心血管事件风险降低18%，比使用磺脲类药物的患者少约4次重大心血管事件（每100人三年）1。
研究人员Ziyad Al-Aly医学博士表示："有大量热情启动GLP-1药物，但对人们停药时发生什么的关注远不够"1。他进一步指出："我们的数据表明这种代谢反弹对心脏健康有害。重启药物有助于恢复部分保护，但仅部分恢复，表明停用药物会留下持久伤害"1。
Discontinuing GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound may quickly erase their cardiovascular protective benefits, according to research from Washington University School of Medicine in St. Louis.1 A three-year study tracking more than 333,000 U.S. veterans with type 2 diabetes found that patients who stopped taking these drugs for two years faced a 22% higher risk of heart attack, stroke, and death compared to those who continued treatment.1 The findings, published in BMJ Medicine in September 2026, underscore the importance of sustained GLP-1 therapy for long-term heart health.1
The research revealed significant patterns in medication adherence and outcomes among users.1 Approximately 26% of GLP-1 users completely discontinued their medication, while roughly 23% experienced treatment interruptions of at least six months.1 Even brief breaks in therapy proved consequential: just six months without treatment weakened cardiovascular protection and increased risk by 4–8%.1 In contrast, patients who continued GLP-1 therapy for the full three years saw their cardiovascular event risk decline by 18%, translating to approximately four fewer major cardiovascular events per 100 patients over three years compared to those taking sulfonylurea medications.1
Dr. Ziyad Al-Aly, a member of the research team, highlighted the gap in current understanding: "There is tremendous enthusiasm for starting GLP-1 drugs, but far less attention to what happens when people stop taking them."1 He further noted that while restarting medication could restore some protection, the recovery remained incomplete. "Our data show this metabolic rebound is harmful to heart health. Restarting the drug helps restore some protection, but only partial, suggesting that stopping the drug leaves lasting damage."1
评论
还没有评论，欢迎留下第一条。